BRPI0816121A2 - Método para reduzir o teor de dímeros em uma composição compreendendo um polipeptídeo de fator vii - Google Patents

Método para reduzir o teor de dímeros em uma composição compreendendo um polipeptídeo de fator vii

Info

Publication number
BRPI0816121A2
BRPI0816121A2 BRPI0816121-6A2A BRPI0816121A BRPI0816121A2 BR PI0816121 A2 BRPI0816121 A2 BR PI0816121A2 BR PI0816121 A BRPI0816121 A BR PI0816121A BR PI0816121 A2 BRPI0816121 A2 BR PI0816121A2
Authority
BR
Brazil
Prior art keywords
factor vii
vii polypeptide
dimer content
composition understanding
reducing dimer
Prior art date
Application number
BRPI0816121-6A2A
Other languages
English (en)
Inventor
Janus Krarup
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38983380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0816121(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0816121A2 publication Critical patent/BRPI0816121A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0816121-6A2A 2007-08-24 2008-08-22 Método para reduzir o teor de dímeros em uma composição compreendendo um polipeptídeo de fator vii BRPI0816121A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114950 2007-08-24
PCT/EP2008/061011 WO2009027334A1 (en) 2007-08-24 2008-08-22 Reduction of dimer content in factor vii polypeptide compositions by heat treatment

Publications (1)

Publication Number Publication Date
BRPI0816121A2 true BRPI0816121A2 (pt) 2014-10-14

Family

ID=38983380

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816121-6A2A BRPI0816121A2 (pt) 2007-08-24 2008-08-22 Método para reduzir o teor de dímeros em uma composição compreendendo um polipeptídeo de fator vii

Country Status (12)

Country Link
US (1) US10047354B2 (pt)
EP (1) EP2201111B1 (pt)
JP (1) JP5577249B2 (pt)
KR (1) KR20100059840A (pt)
CN (1) CN101802187B (pt)
AU (1) AU2008292264A1 (pt)
BR (1) BRPI0816121A2 (pt)
CA (1) CA2697248A1 (pt)
ES (1) ES2520046T3 (pt)
MX (1) MX2010001740A (pt)
RU (1) RU2483079C2 (pt)
WO (1) WO2009027334A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3641115A1 (de) 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
WO2001077141A1 (en) * 2000-04-06 2001-10-18 Novo Nordisk A/S Shock heat treatment of polypeptides
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
KR20040065278A (ko) 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20070037966A1 (en) * 2004-05-04 2007-02-15 Novo Nordisk A/S Hydrophobic interaction chromatography purification of factor VII polypeptides
EP1750750B1 (en) * 2004-06-01 2012-02-01 Ares Trading S.A. Method of stabilizing proteins
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
WO2006114448A2 (en) 2005-04-28 2006-11-02 Novo Nordisk Health Care Ag A closed container comprising an activated factor vii polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
US20080268521A1 (en) 2005-09-01 2008-10-30 Novo Nordisk Healthcare A/G Purification of Coagulation Factor VII Polypeptides

Also Published As

Publication number Publication date
US10047354B2 (en) 2018-08-14
EP2201111B1 (en) 2014-08-13
JP5577249B2 (ja) 2014-08-20
MX2010001740A (es) 2010-03-10
CN101802187B (zh) 2014-04-09
CN101802187A (zh) 2010-08-11
RU2010109343A (ru) 2011-09-27
KR20100059840A (ko) 2010-06-04
ES2520046T3 (es) 2014-11-11
EP2201111A1 (en) 2010-06-30
RU2483079C2 (ru) 2013-05-27
WO2009027334A1 (en) 2009-03-05
US20110003363A1 (en) 2011-01-06
JP2010536921A (ja) 2010-12-02
CA2697248A1 (en) 2009-03-05
AU2008292264A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
BRPI0921577A2 (pt) Métodos e composições para controle de peso e para aperfeiçoar controle glicêmico
BRPI0918504A2 (pt) composições de cura para materiais de revestimento compósito
BRPI0906547A2 (pt) composição refrigerante e kit para uma composição refrigerante
BRPI0921346A2 (pt) método de controle de um ciclo para correção de fator de potência
BRPI0814157A2 (pt) Composição de catalisador e processos para a preparação e uma composição de catalisador e para desalquilação de etil-benzeno
BRPI0917894A2 (pt) composição de múltiplas camadas para máscara respiratória
BRPI0918838A2 (pt) processos para preparação de composições de polipeptídeos purificados
PT2152237E (pt) Nova composição farmacêutica
BRPI0818007A2 (pt) composição para regular o metabolismo lipídico
BRPI0822622A2 (pt) Uma composição que contém levedura usada para aditivo de alimento de bovinos
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI0823276A2 (pt) Método para aplicar uma composição de indicador a uma área desejada de um substrato
PL2234942T3 (pl) Kompozycje cementowe do nakładania na korpusy o strukturze plastra miodu
BRPI0819946A2 (pt) Composição de matéria e método para preparar uma composição tensoativa
PL2173944T3 (pl) Kompozycja wypełniacza
DK2305275T3 (da) Væskesammensætning omfattende cisplatinkoordinerende forbindelse
BRPI0921744A2 (pt) revestimento refletivo e método para aplicar um revestimento refletivo em uma estrutura
HUE050793T2 (hu) Rekombináns HCG-t tartalmazó gyógyászati készítmény
ZA201007871B (en) Lightweight structural concrete composition
BRPI0909892A2 (pt) composição vedante
BRPI0910059A2 (pt) Composição sólida para controle de praga
BR112012004137A2 (pt) método para ligar uma composição de borracha a um substrato, e, composição
BR112012002975A2 (pt) composição para o controle de pragas
BRPI0919038A2 (pt) composição em pó para revestimento
BR112013014722A2 (pt) composição de revestimento e método para reduzir o teor de composto orgânico volátil de uma composição de revestimento

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]